| Today's Open | $79.07 |
|---|---|
| Previous Close | $78.80 |
| Daily Range | $78.03 - $80.42 |
| 52-Week Range | $38.44 - $87.47 |
| Market Cap | $17.7B |
| P/E Ratio | -33.39 |
| Dividend (Yield) | $0.00 (0.0%) |
| Volume | 668,389 |
| Average Daily Volume | 1,847,982 |
| Current FY EPS | -$2.22 |
Sector
Healthcare
Industry
Drugs
Vertex Pharmaceuticals (VRTX) Description
The Company is in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases. Website: http://www.vrtx.com/
News & Commentary
Gilead's Potential Megablockbuster Raises the Bar
Gilead's sofosbuvir will get priority review, which brings it one step closer to upping the bar in hepatitis C treatment.Game-Changing Hep C Pill Closer to Approval
Gilead gets FDA priority review status for its game-changing hepatitis C drug.Vertex Pharmaceuticals Incorporated Presents at Goldman Sachs 34th Annual Global Healthcare Conferen
Vertex Pharmaceuticals Incorporated Presents at Goldman Sachs 34th Annual Global Healthcare Conference, Jun-11-2013 10:00 AMVRTX's Top Competitors
(1.40%)
(-0.53%)
(-0.56%)
(-1.21%)